In addition, promising efficacy was showed with a new covalent binding EGFR-TKI (tyrosine kinase inhibitors), CM93, targeting EGFR alterations in preclinical trials (147), while other TKIs, in phase II trials, failed to show improvement in patients with non-progressive or recurrent glioblastoma (135, 148). Here, EGFR is linked to glioblastoma.